The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of ...
In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...
Siloton’s handheld OCT system could soon be used for home-based monitoring of retinal disease, and may one day find its way onto future space missions ...
The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of neovascular AMD. Primary endpoints include the safety and tolerability of ...
Patients being treated for neovascular age-related macular degeneration (nAMD) appear to have less likelihood of submacular hemorrhage (SMH) when their most recent biologic agent was faricimab, ...
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes -- Positive Topline Results ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback